Antipsychotics (APDs) represent a core treatment for severe mental disorders (SMEs). Providing symptomatic relief, APDs do not exert therapeutic effects on another clinically significant domain of serious mental disorders, cognitive impairment. Moreover, adverse metabolic effects (diabetes, weight gain, dyslipidemia, and increased cardiovascular risk) are common during treatment with APDs. Among pharmacological candidates reversing APD-induced metabolic adverse effects, glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs), approved for both diabetes and recently for obesity treatment, stand out due to their favorable effects on peripheral metabolic parameters. Interestingly, GLP-1 RAs are also proposed to have pro-cognitive effects. Particularly in terms of dual therapeutic mechanisms potentially improving both central nervous system (CNS) deficits and metabolic burden, GLP-1 RAs open a new perspective and assume a clinically advantageous position.

抗精神病药 (APD) 代表了严重精神障碍 (SME) 的核心治疗方法。提供症状缓解，APDs 不会对另一个临床上重要的严重精神障碍领域，认知障碍产生治疗作用。此外，在使用 APD 治疗期间，不良代谢作用（糖尿病、体重增加、血脂异常和心血管风险增加）很常见。在逆转 APD 诱导的代谢不良反应的药理学候选药物中，胰高血糖素样肽-1 (GLP-1) 受体激动剂 (GLP-1 RAs) 因其对外周血的有利作用而脱颖而出，该药已被批准用于糖尿病和最近用于肥胖症治疗代谢参数。有趣的是，GLP-1 RAs 也被认为具有促认知作用。